A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC)
Latest Information Update: 29 Jun 2023
At a glance
- Drugs Masitinib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 26 Jun 2023 Results presented in an AB Science media release.
- 26 Jun 2023 According to an AB Science media release, announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from this phase 3 study of AB12003. This new European patent provides intellectual property protection for masitinib in the treatment of mCRPC until 2042.
- 04 Dec 2021 This trial has been completed in Greece, according to European Clinical Trials Database record.